Zacks: Analysts Expect BioLife Solutions, Inc. (NASDAQ:BLFS) Will Post Earnings of -$0.06 Per Share

Brokerages forecast that BioLife Solutions, Inc. (NASDAQ:BLFS) will announce earnings per share of ($0.06) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for BioLife Solutions’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.08). BioLife Solutions reported earnings per share of ($0.04) in the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The company is expected to announce its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that BioLife Solutions will report full year earnings of $0.06 per share for the current financial year, with EPS estimates ranging from $0.03 to $0.09. For the next fiscal year, analysts expect that the firm will post earnings of $0.09 per share, with EPS estimates ranging from ($0.22) to $0.36. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Wednesday, August 11th. The medical equipment provider reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.15). The company had revenue of $31.20 million during the quarter, compared to the consensus estimate of $28.32 million. BioLife Solutions had a negative return on equity of 0.07% and a net margin of 4.72%.

BLFS has been the subject of a number of recent research reports. KeyCorp boosted their price objective on BioLife Solutions from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, August 13th. TheStreet raised BioLife Solutions from a “d” rating to a “c” rating in a report on Wednesday, September 1st. Zacks Investment Research raised BioLife Solutions from a “strong sell” rating to a “hold” rating in a report on Wednesday. Cowen boosted their price target on BioLife Solutions from $50.00 to $64.00 and gave the stock an “outperform” rating in a report on Friday, August 13th. Finally, Northland Securities boosted their price target on BioLife Solutions from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, September 2nd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $59.13.

Shares of NASDAQ:BLFS traded up $1.28 during mid-day trading on Friday, reaching $40.15. 6,845 shares of the company traded hands, compared to its average volume of 341,696. The company’s 50 day moving average price is $47.60 and its 200-day moving average price is $41.51. The firm has a market cap of $1.63 billion, a PE ratio of 647.94, a PEG ratio of 91.16 and a beta of 1.42. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.07 and a quick ratio of 3.25. BioLife Solutions has a 52 week low of $26.58 and a 52 week high of $60.67.

In other BioLife Solutions news, CEO Michael Rice sold 11,461 shares of the company’s stock in a transaction on Thursday, August 5th. The stock was sold at an average price of $48.37, for a total value of $554,368.57. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph C. Schick sold 3,250 shares of the stock in a transaction on Thursday, October 7th. The stock was sold at an average price of $40.04, for a total value of $130,130.00. The disclosure for this sale can be found here. Insiders sold a total of 233,282 shares of company stock worth $10,832,983 in the last ninety days. 5.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC bought a new stake in BioLife Solutions during the first quarter valued at about $2,684,000. Envestnet Asset Management Inc. purchased a new position in shares of BioLife Solutions in the 1st quarter worth approximately $400,000. Rhumbline Advisers raised its stake in shares of BioLife Solutions by 2.5% during the 1st quarter. Rhumbline Advisers now owns 13,972 shares of the medical equipment provider’s stock worth $503,000 after acquiring an additional 335 shares in the last quarter. Swiss National Bank raised its stake in shares of BioLife Solutions by 2.0% during the 1st quarter. Swiss National Bank now owns 59,900 shares of the medical equipment provider’s stock worth $2,156,000 after acquiring an additional 1,200 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of BioLife Solutions by 6.5% during the 1st quarter. BlackRock Inc. now owns 1,312,818 shares of the medical equipment provider’s stock worth $47,262,000 after acquiring an additional 80,147 shares in the last quarter. 68.31% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

Featured Article: Why are percentage gainers important?

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.